Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease

Annals of Pharmacotherapy

Volumn 44, Issue 5, 2010, Pages 871-877

  Abel, Cheryl ^a   Desilets, Alicia R ^a   Willett, Kristine ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Dexlansoprazole; Proton pump inhibitor

Indexed keywords

CLOPIDOGREL; DEXILANT; DEXLANSOPRAZOLE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; ESOPHAGITIS; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; NAUSEA; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; DRUG INTERACTIONS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 77951609656     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M685     Document Type: Review

References (29)

1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-717 DOI 10.1136/gut.2004.051821 (Pubitemid 40559260)
2. DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200. DOI 10.1111/j.1572-0241.2005.41217.x
3. El-Serag HB. Epidemiology of non-erosive reflux disease. Digestion 2008;78(suppl 1):6-10. DOI 10.1159/000151249
4. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005;22:79-94. DOI 10.1111/j.1365-2036.2005.02531.x
5. Product information. Kapidex (dexlansoprazole). Deerfield, IL: Takeda Pharmaceuticals America, Inc., January 2009.
6. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29:928-937 DOI 10.1111/j.1365-2036.2009.03984.x
7. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305. DOI 10.1146/annurev.pa.35.040195.001425
8. Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol 2009;49:444-454 DOI 10.1177/ 0091270008330155
9. Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009;29:1261-1272 DOI 10.1111/j.1365-2036.2009.04013.x
10. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009;25:627-638 DOI 10.1185/03007990802693883
11. Sachs G. Physiology of the parietal cell and therapeutic implications. Pharmacotherapy 2003;23(10 pt 2):68S-73S. DOI 10.1592/phco.23.13.68S.31931
12. Product information. Prilosec (omeprazole). Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2008.
13. Product information. Prevacid (lansoprazole). Deerfield, IL: Takeda Pharmaceuticals America, Inc., July 2009.
14. Product information. Nexium (esomeprazole). Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2009.
15. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther 2009;29:824-833 DOI 10.1111/j.1365-2036.2009.03979.x
16. Product information. Protonix (pantoprazole). Philadelphia, PA: Wyeth Pharmaceuticals Inc., May 2008.
17. Product information. Aciphex (rabeprazole). Woodcliff Lake, NJ: Eisai, Inc., January 2009.
18. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5:181-202. DOI 10.1517/phgs.5.2.181.27483
19. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Invest 2009;29:35-50.
20. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009; 43(7):1266-1274. DOI 10.1345/aph.1M051
21. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260 DOI 10.1016/j.jacc.2007.06.064
22. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-1153
23. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-2329 DOI 10.1161/CIRCULATIONAHA.109.873497
24. Klein CE, Chiu YL, Cai Y, et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol 2008;48:553-562 DOI 10.1177/0091270007313392 (Pubitemid 351503512)
25. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953 DOI 10.1001/jama.296.24.2947 (Pubitemid 46021498)
26. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009;104(suppl 2):S5-9. DOI 10.1038/ajg.2009.45
27. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29:731-741 DOI 10.1111/j.1365-2036.2009. 03933.x
28. Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29:742-754 DOI 10.1111/j.1365-2036.2009.03954.x
29. Red book: pharmacy's fundamental reference, 2009 edition. Montvale, NJ: Thompson Reuters, 2009.